Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ViroPharma (VPHM) announced that routine prophylactic use of Cinryze (C1 esterase inhibitor [human]) provided effectiveness and maintained a generally favorable safety profile in the treated subjects with hereditary angioedema (HAE) in a study.
Subscribe to our email newsletter
The open-label, multicenter extension study was designed to evaluate the safety and efficacy of Cinryze and involved 146 HAE subjects, who were treated for up to 2.6 years in centers across US.
The subjects were treated with Cinryze 1000 units every 3 to 7 days based on the decision of the investigator.
HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of a human plasma protein called C1 inhibitor.
The treated subjects on an average received 1.4 injections per week throughout the study period and the efficacy of Cinryze was directly correlated with the interval between injections.
San Diego University of California professor of medicine and program director of the Allergy and Immunology Fellowship Program Bruce L. Zuraw said the results of the study reinforce the efficacy and safety profile of Cinryze when used up to 2.6 years and the clinically relevant impact Cinryze can offer to people living with HAE who are experiencing recurrent attacks.
"These data suggest that prophylactic Cinryze should be considered by the physician for any patient with hereditary angioedema who requires or desires prophylactic treatment," Zuraw added.